What is the average price target for NUCOR CORP (NUE) stock?
22 analysts have analysed NUE and the average price target is 189.07 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 162.38.
NYSE:NUE • US6703461052
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NUCOR CORP (NUE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-16 | UBS | Maintains | Neutral -> Neutral |
| 2026-03-02 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-28 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-09 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-12-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-10 | Jefferies | Maintains | Buy -> Buy |
| 2025-12-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-14 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2025-10-30 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-29 | UBS | Maintains | Buy -> Buy |
| 2025-10-29 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-29 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-18 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-15 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-15 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-14 | Wells Fargo | Initiate | Equal-Weight |
| 2025-07-31 | Jefferies | Upgrade | Hold -> Buy |
| 2025-07-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-02 | BMO Capital | Upgrade | Market Perform -> Outperform |
| 2025-05-29 | UBS | Maintains | Buy -> Buy |
| 2025-04-16 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 34.714B -16.38% | 30.734B -11.46% | 32.494B 5.73% | 36.089B 11.06% | 37.796B 4.73% | 38.474B 1.79% | 38.937B 1.20% | |
| EBITDA YoY % growth | 7.399B -36.04% | 4.335B -41.41% | 4.139B -4.52% | 5.639B 36.24% | 6.093B 8.05% | 6.26B 2.74% | 6.23B -0.48% | |
| EBIT YoY % growth | 6.23B -40.70% | 2.979B -52.19% | 2.659B -10.74% | 4.02B 51.18% | 4.392B 9.25% | 4.524B 3.01% | 4.75B 5.00% | |
| Operating Margin | 17.95% | 9.69% | 8.18% | 11.14% | 11.62% | 11.76% | 12.20% | |
| EPS YoY % growth | 17.99 -37.38% | 8.85 -50.81% | 7.78 -12.09% | 12.13 55.85% | 13.57 11.92% | 13.70 0.93% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.88 274.27% | 3.37 27.30% | 3.08 17.29% | 2.62 51.32% | 2.77 -3.97% | 2.93 -13.17% | 3.03 -1.78% | 3.05 16.51% |
| Revenue Q2Q % growth | 8.987B 14.78% | 9.421B 11.41% | 9.092B 6.70% | 8.499B 10.56% | 9.03B 0.48% | 9.218B -2.15% | 9.422B 3.63% | 9.415B 10.78% |
| EBITDA Q2Q % growth | 1.352B 95.38% | 1.491B -9.80% | 1.401B -29.56% | 1.235B -38.50% | 1.408B 4.14% | 1.452B -2.62% | 1.495B 6.71% | 1.456B 17.89% |
| EBIT Q2Q % growth | 964.17M 197.58% | 1.107B 20.46% | 1.012B 13.96% | 859.12M 62.71% | 912.7M -5.34% | 952.33M -13.97% | 971.35M -4.02% | 959.56M 11.69% |
All data in USD
22 analysts have analysed NUE and the average price target is 189.07 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 162.38.
NUCOR CORP (NUE) will report earnings on 2026-04-27, after the market close.
The consensus EPS estimate for the next earnings of NUCOR CORP (NUE) is 2.88 USD and the consensus revenue estimate is 8.99B USD.
The expected long term growth rate for NUCOR CORP (NUE) is 5.31%.